Duchenne muscular dystrophy is an X-linked recessively inherited condition in which there is progressive degeneration of the skeletal muscle fibres, in association with loss of the muscle fibres, fibrosis and replacement with fat. The clinical presentation is at about the age of four or five years, and by the age of about 10, the children become unable to walk. Relentless progression of the disease leads to death in most cases by about the age of 16 to 18 years.
At present the biochemical defect in Duchenne muscular dystrophy is unknown, and it is therefore impossible to offer a definitive treatment. Conceivably, however, there may be a way of affecting the secondary processes occurring in the disease, and to reduce the degree of fibrosis might be of help.
Experience in controlling muscle fibrosis had been gained in the Muscular Dystrophy Research Laboratories in Newcastle in treating a patient with myosclerosis. This rare condition presented with progressive wasting and contracture of the muscles, which had a woody feeling and showed marked fibrosis. The degree of contraction could be reduced by penicillamine therapy, and when the therapy was reduced the contractures returned. It was therefore decided to mount a trial of penicillamine therapy in Duchenne muscular dystrophy. Fifteen similar pairs of patients of all ages have been incorporated into the trial, and randomly allocated to placebo or penicillamine groups.
Penicillamine was gradually increased over a two-month period to a maintenance dose of 20 mg/kg per day in divided doses. The patients, and the 'physician assessors', are unaware of the nature of the preparation that the patient is taking, and the latter have surveyed various features of muscle strength with a dynomometer, the degree of contracture of the muscles, and the time to perform various standard procedures. The 'physician manager' is aware of the preparation that the patients are taking, and is responsible for arranging the dosage of the drug and surveying for side-effects.
The trial has now been in progress for 11 months, and an interim assessment of the results to six months has been made. The only significant side-effect encountered has been the presence of proteinuria of significant degree in 2 patients receiving the active preparation. No other sideeffects, and in particular no evidence of thrombocytopenia, rashes or impairment of taste have been encountered. Analysis of the results to six months have not indicated any statistically significant difference between the two treatment groups, but it is planned to continue the trial to one year before breaking the code and fully analysing the data.
DISCUSSION

Dr J W Czekalowski (Leeds): When Professor
Bradley referred to Duchenne type of dystrophy, was he thinking of the type in which muscles of the limb girdles are affected? In the past, two forms of such muscular dystrophy were recognizeddefined by the involvement of the shoulder or the hip muscle girdle, respectively. Are these forms now linked together, taken over by one name, that of Duchenne?
Professor Bradley: No, there are six different sorts of muscular dystrophy. The Duchenne boyhood, X-linked recessive form is the commonest in terms of its incidence, and it is different from the limb girdle varieties referred to by Dr Czekalowski and, also, from the facioscapulohumeral variety and so on. In this study we are dealing only with the severe, X-linked recessively inherited muscular dystrophy.
